Use of ciprofibrate in dogs with hypertriglyceridemia

Abstract

The objective of this study was to evaluate the effect of ciprofibrate on serum triglyceride concentrations in canine patients. A sample size of 21 canines was study, that had a diagnosis of familial dyslipidemia, and was established with triglyceride levels above 500mg/dl, treatment with ciprofibrate was evaluated at 2 months. The analysis of the variation in triglyceride levels was performed using the non-parametric Wilcoxon matched-pairs signed-rank test. The Wilcoxon test revealed that the triglyceride concentration decreased significantly after two months of treatment with ciprofibrate; from 621 (512 to 1046)mg/dL to 136 (67 to 215)mg/dL (p <0.0001). The difference in medians was -482.0md/dL with a 97.3% confidence interval of -579.0 to -443.0mg/dL. It was concluded that the use of drugs such as ciprofibrate in the treatment of patients with familial hiperlipidemia, had a significant decrease in serum triglyceride concentrations, without generating adverse reactions in this study.